Solventum Mixed Picture: Quarterly Revenue and Net Income Climb While Half-Year Trail Prior Year

Bottom line

Solventum Corporation, trading under the symbol "SOLV" on the New York Stock Exchange, filed a quarterly report on 10-Q for period-ended-2026-06-30, identified by accession 0001964738-26-000047 and CIK 0001964738, presenting its unaudited condensed consolidated financial statements for the three months ended the three months ended June 30, 2026 alongside the comparative three months ended the three months ended June 30, 2025, and for the six-month year-to-date period ended the six months ended June 30, 2026 alongside the comparative six-month year-to-date period ended the six months ended June 30, 2025.

The reporting scope is therefore two paired windows: a single quarter and the year-to-date half year, each compared with the equivalent prior-year window. Within those windows, four headline measures are reported: Revenues, Operating Income (Loss), Net Income (Loss) Attributable to Parent, and Earnings Per Share, Diluted. Revenues for the three months ended June 30, 2026 were $2,209,000,000 USD, against $2,161,000,000 USD for the three months ended June 30, 2025, with Revenues for the six months ended June 30, 2026 of $4,216,000,000 USD compared with $4,231,000,000 USD for the six months ended June 30, 2025.

Operating Income (Loss) was $181,000,000 USD for the three months ended June 30, 2026 versus $214,000,000 USD for the three months ended June 30, 2025, and $262,000,000 USD for the six months ended June 30, 2026 versus $367,000,000 USD for the six months ended June 30, 2025. Net Income (Loss) Attributable to Parent was $92,000,000 USD for the three months ended June 30, 2026 compared with $90,000,000 USD for the three months ended June 30, 2025, and $105,000,000 USD for the six months ended June 30, 2026 compared with $227,000,000 USD for the six months ended June 30, 2025.

30 per diluted share USD/SHARES for the six months ended June 30, 2025. S. Securities and Exchange Commission requirements, include transactions with the Company's former parent disclosed as related party transactions in Note 16, and are organized across three reportable business segments — MedSurg, Dental Solutions, and Health Information Systems.

The interim financial information is unaudited but, in management's opinion, reflects all adjustments necessary for a fair statement of the Company's consolidated financial position, results of operations, and cash flows for the periods presented. The filing evidence contains no peer or industry comparison. Related-party context, segment structure, and references to other notes such as Note 3, Note 10, Note 11, and Note 12 are present within the filing, alongside Part II items Item 1, Item 1A, Item 2, Item 3, Item 4, Item 5, and Item 6, but those notes and items are not enumerated within this section.

The filing evidence does not attribute this change to any single cause.

Financial performance

Solventum Corporation's three-month reporting period delivered revenue of $2,209,000,000 USD against a prior-year comparative of $2,161,000,000 USD, a directionally higher top line on a quarter-over-quarter basis. The full six-month year-to-date frame tells a different story: revenue for the six months ended June 30, 2026 came in at $4,216,000,000 USD, lower than the prior-year comparative of $4,231,000,000 USD. Operating Income (Loss) on the quarter was $181,000,000 USD versus $214,000,000 USD a year earlier, a directionally lower quarter result; for the six-month frame, operating income was $262,000,000 USD against $367,000,000 USD, again a lower reading than the prior year. The bottom line followed a similar pattern. Net Income (Loss) Attributable to Parent was $92,000,000 USD on the quarter versus $90,000,000 USD a year ago, a directionally higher quarter result, while the six-month figure was $105,000,000 USD versus $227,000,000 USD, directionally lower than the prior year. Both periods remained in profit territory, with the year-to-date line staying profitable against the prior year's profit. Diluted Earnings Per Share registered $0.53 per diluted share USD/SHARES for the three-month reporting period against $0.51 per diluted share USD/SHARES a year earlier, a directionally higher reading; the six-month diluted EPS was $0.60 per diluted share USD/SHARES versus $1.30 per diluted share USD/SHARES, directionally lower than the prior year. Neither figure crossed into a loss, and both stayed within the profit-to-profit transition authorized by the comparative framework. The filing evidence does not attribute this change to any single cause.

Management's narrative inside the filing anchors several accounting-context items that frame those headline results without explaining the gaps between them. Rounding policy is disclosed: amounts are rounded to the nearest million, and component sums may not foot to reported totals, which is a normal caveat for interim presentations. New accounting pronouncements are summarized in a table that includes an ASU on income-statement expense disaggregation, for which the Company is currently assessing impact, and an internal-use software subtopic update whose early adoption did not have a material impact on the consolidated financial statements. Revenue recognition context highlights that unearned revenue relates primarily to software licenses recognized over time, and operating lease revenue from durable medical devices — reported within the MedSurg segment — contributed a portion of operating lease revenue across the three- and six-month periods, with the prior-year figures disclosed at lower levels. Customer concentration is disclosed as immaterial, with no single customer accounting for more than a stated threshold of revenues in either window. Capital allocation context is provided by the Acera contingent payment, classified within the lower fair-value tier, and by the earlier divestiture of the Purification and Filtration business to Thermo Fisher Scientific, Inc., supported by transition service agreements of up to a stated multi-month term. Supply chain financing obligations confirmed valid to the financial institution under the SCF program were less than a stated threshold as of the balance-sheet date, and finance-lease right-of-use assets were recorded at a level comparable to the related liability. The filing evidence contains no peer or industry comparison.

Management commentary inside this Form 10-Q for fiscal period period-ended-2026-06-30 (accession 0001964738-26-000047) is limited to the disclosures cited above and does not address outlook, guidance, or expectations for the next quarter, and no analyst estimates are referenced inside this filing. A separate SMITH A O CORP (AOS) interim filing showing softer revenue, operating income, net income, and diluted EPS on both the quarter and six-month year-to-date windows illustrates how comparable mixed-period moves can appear in peer 10-Q disclosures.

Operating drivers and segments

- Solventum reports through three aligned segments: MedSurg, Dental Solutions, and Health Information Systems. - Operating lease revenue from durable medical device rentals sits inside MedSurg, separate from software and other rental lines. - Consolidated revenues for the three-month reporting period were $2,209,000,000 USD, against $2,161,000,000 USD for the prior-year comparative for the three-month reporting period, and the reported direction is an increase. - Consolidated revenues for the six-month year-to-date period were $4,216,000,000 USD, against $4,231,000,000 USD for the prior-year comparative for the six-month year-to-date period, and the reported direction is a decrease. - Consolidated operating income for the three-month reporting period was $181,000,000 USD, against $214,000,000 USD for the prior-year comparative for the three-month reporting period; the reported direction is a decrease. - Consolidated operating income for the six-month year-to-date period was $262,000,000 USD, against $367,000,000 USD for the prior-year comparative for the six-month year-to-date period; the reported direction is a decrease.

- Management describes the company profile in terms of material science, data science, and digital capabilities serving three end markets. - Operating lease revenue from MedSurg rentals is disclosed for both the quarter and the half year, against the corresponding prior-year windows. - Customer concentration is presented as immaterial, with no customer reaching the disclosure threshold in either the quarter or the half year. - New accounting standards disclosed in the new-accounting-pronouncements table have been described as not material to the consolidated statements on early adoption. - The Purification and Filtration divestiture to Thermo Fisher generated transition service income recognized within selling, general and administrative expenses, partially offsetting transition service costs. - Goodwill movements are tied to translation and other activity, including foreign exchange and purchase-accounting adjustments for the Acera acquisition. - Supply chain financing remains voluntary and supplier-driven, with no on-balance-sheet change in trade payable terms beyond the program's existing scope.

The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison.

The consolidated pattern — quarter-over-quarter revenue higher and operating income lower, half-year-over-half-year revenue lower and operating income lower — is consistent with the management discussion of mix shift, divestiture timing, and lease-versus-license composition, but no single driver is identified for any individual movement. A cross-check of healthcare issuers in the same window, for example AES Corp interim filing shows higher revenue and a loss-to-profit swing on net income and diluted EPS for both the quarter and the six-month year-to-date period, while capital and dividend outflows also stepped up, shows how different segment mixes and divestiture timing relate to different operating-income trajectories across the sector.

Unknowns: the filing does not separately disclose MedSurg, Dental Solutions, or Health Information Systems revenue or operating income at the segment level in the cataloged evidence, so segment-level margin movement cannot be evaluated; the cash flow hedging reclassifications in Note 10 and the tax reclassifications in Note 11 are referenced but the magnitude is not provided here, leaving the after-tax operating picture incomplete.

Cash flow and capital

- Reported fact — Operating cash flow for the six months ended June 30, 2026 was $38,000,000 USD, compared with $198,000,000 USD in the six months ended June 30, 2025. Both years show an inflow, and the comparison direction authorized for this filing is a decrease in operating cash flow. The filing evidence does not attribute this change to any single cause.

The filing evidence does not attribute this change to any single cause. - Reported fact — Investing activities used -$164,000,000 USD over the six months ended June 30, 2026, versus an outflow of -$224,000,000 USD in the prior-year window. Both periods are negative, and the authorized direction is a smaller outflow year over year.

- Reported fact — Financing activities used -$350,000,000 USD during the six months ended June 30, 2026, against an outflow of -$249,000,000 USD in the six months ended June 30, 2025. Both periods are negative, with the authorized direction showing a decrease in the cash figure (that is, the absolute outflow was larger this half). - Management explanation — Disclosed within Note 12, the share repurchase program authorizes purchases of the Company's outstanding common stock.

Under that program the Company repurchased shares of its common stock for total consideration of approximately (omitted) million and (omitted) million through open market repurchases during the three and six months ended June (omitted), respectively. Reported fact — Cash spent on repurchases was $355,000,000 USD for the six months ended June 30, 2026, against $0 USD in the prior-year window. The authorized direction is an increase, consistent with the Company putting new authorizations to work in the current half.

- Reported fact — Capital spending was $167,000,000 USD for the six months ended June 30, 2026, compared with $219,000,000 USD for the six months ended June 30, 2025. Both periods are positive, and the authorized direction is a decrease. The filing evidence does not disclose what mix of maintenance, capacity, or efficiency projects drove the year-over-year shift.

The filing evidence does not attribute this change to any single cause. - Reported fact — The balance sheet at the balance sheet date of June 30, 2026 showed cash and equivalents of $403,000,000 USD, accounts payable of $701,000,000 USD, and long-term debt (excluding current maturities) of $4,573,000,000 USD. The Company also disclosed a voluntary supply chain financing program whose confirmed obligations outstanding represented less than (omitted) million as of June (omitted); those obligations remain within accounts payable, with the related settlements continuing to flow through operating activities.

- Analyst inference — Read together, the three cash-flow lines point to operating cash funding both investing outflows and a heavier financing outflow, while share repurchases stepped up versus a near-zero prior-year base and capital spending receded modestly. The combined effect on cash on the balance sheet is visible in the cash and equivalents line at the balance sheet date of June 30, 2026. - Counter-evidence — Management commentary flags a September (omitted) divestiture of the Purification and Filtration business to Thermo Fisher Scientific, with transition service agreements extending up to (omitted) months from closing; transition service income recognized during the three and six months ended June (omitted) was disclosed only as approximately (omitted) million and (omitted) million respectively, with no line-by-line offsetting cash-flow detail in the filing evidence.

- Unknowns — The filing evidence does not attribute this change to any single cause. The filing does not break out how much of the investing or financing movement relates to the divestiture proceeds, the share repurchase pace, debt issuance costs, or lease activity, and no peer or industry comparison is available. The filing evidence contains no peer or industry comparison.

Peer and historical context

- Solventum's six-month year-to-date operating cash flow was $38,000,000 USD, lower than the prior-year comparable of $198,000,000 USD for the six months ended June 30, 2025, indicating softer cash generation despite the company remaining cash-positive on operations. - Revenues for the six months ended June 30, 2026 came in at $4,216,000,000 USD, down from $4,231,000,000 USD a year earlier, while the three-month window showed a reversal in direction: $2,209,000,000 USD exceeded $2,161,000,000 USD for the three months ended June 30, 2025.

- Operating income moved lower on both lenses, at $262,000,000 USD versus $367,000,000 USD for the year-to-date and $181,000,000 USD versus $214,000,000 USD for the quarter, compressing margin headroom on the six-month view even as the quarter's top line expanded. - Net income attributable to parent mirrored the operating pattern: $105,000,000 USD trailed $227,000,000 USD, while $92,000,000 USD outpaced $90,000,000 USD, suggesting the quarter's recovery has not yet been enough to lift the six-month bottom line above last year.

- The contrast between softer year-to-date results and a firmer quarter is the same shape visible in several peers reporting similar the three months ended June 30, 2026 dynamics, such as CMS Energy Reports Softer Bottom Line Against Higher Contract Revenue in the period-ended filing, where one period's revenue direction ran counter to the other. - Any read that the latest quarter marks a clean inflection is limited by the fact that operating income on the quarter still printed below its prior-year level, so profitability has not fully caught up with the top-line rebound.

- The six-month decline in operating cash flow alongside a year-to-date drop in operating income reduces the room to attribute the year-to-date weakness to a single item. The filing evidence does not attribute this change to any single cause. - the filing does not provide comparable figures for healthcare-technology peers, so placing Solventum's margins or growth against industry benchmarks is not possible from this evidence alone.

The filing evidence contains no peer or industry comparison. - Segment-level drivers behind the revenue and operating-income shifts are not separately broken out for these dimensions in the cited notes. The filing evidence does not disclose segment-level detail for this dimension.

Readers comparing this with earlier coverage, including SMITH A O CORP (AOS) Reports Softer Revenue, Operating Income, Net Income, and Diluted EPS on Both the Quarter and Six-Month Year-to-Date Views, should note that Solventum's quarter-versus-prior-year pattern differs in direction from a peer whose quarter and year-to-date both softened, reinforcing that this section's picture is company-specific rather than industry-wide.

Scenario analysis

- In the base case, Solventum Corp continues on the trajectory visible in the most recent 10-Q for the three months ended June 30, 2026, with top-line momentum from the quarter carrying into the remainder of the fiscal year while the softer year-to-date comparison sets the pacing for the back half.

- The upside case leans on the favorable quarter-over-quarter direction already authorized in the reported comparisons: Revenues for the three months ended June 30, 2026 versus the three months ended June 30, 2025 is an increase, and Net Income (Loss) Attributable to Parent for the three months ended June 30, 2026 versus the three months ended June 30, 2025 is an increase, with both periods registering profit. Reported quarterly revenue for the three months ended June 30, 2026 was $2,209,000,000 USD, against a prior-year comparative of $2,161,000,000 USD, and quarterly net income was $92,000,000 USD, against $90,000,000 USD. If that quarterly cadence holds and any momentum in the three-month window compounds, the full-year picture can re-rate higher even though the year-to-date view is softer.

- The downside case is anchored in the year-to-date softness that the same filing discloses: Revenues for the six months ended June 30, 2026 versus the six months ended June 30, 2025 is a decrease, and Net Income (Loss) Attributable to Parent for the six months ended June 30, 2026 versus the six months ended June 30, 2025 is a decrease, with both periods still in profit. Reported revenue for the six months ended June 30, 2026 was $4,216,000,000 USD, against $4,231,000,000 USD, and net income was $105,000,000 USD, against $227,000,000 USD. The filing evidence does not attribute this change to any single cause.

The asymmetry between the three-month and six-month views is the central planning tension for management and readers building a conditional view of the rest of the period. The quarter carries an authorized direction of increase on both the top line and the bottom line, while the year-to-date window carries an authorized direction of decrease on both lines, with the profit-to-profit transition preserved on every comparison. Readers weighing peers against this profile can cross-check the pattern against an analogous interim filing such as SMITH A O CORP (AOS) Reports Softer Revenue, Operating Income, Net Income, and Diluted EPS on Both the Quarter and Six-Month Year-to-Date Views in Form (Accession for contrast.

The base, upside, and downside paths therefore depend on whether the second half preserves the recent quarterly cadence. The cited note on tax effects discusses reclassifications of foreign currency forward contract amounts into cost of sales and an unfavorable geographic mix of earnings, and the cited note on related parties references transition agreement activity with Buyer, but neither is presented as the driver of the year-to-date softness. The filing evidence does not attribute this change to any single cause.

Risks and what to watch

- Reported facts: Solventum reported mixed direction across its two reported windows. Revenues for the six months ended June 30, 2026 were $4,216,000,000 USD, below $4,231,000,000 USD for the six months ended June 30, 2025. In contrast, Revenues for the three months ended June 30, 2026 were $2,209,000,000 USD, above $2,161,000,000 USD for the three months ended June 30, 2025. Net income attributable to the parent showed the same pattern: $105,000,000 USD for the six months ended June 30, 2026, compared with $227,000,000 USD for the six months ended June 30, 2025, while the quarterly figure rose to $92,000,000 USD from $90,000,000 USD. The divergence between the full-period and quarterly views is the main risk signal in the filing, although profitability remained positive in every reported period.

- Management explanations: The cited note describes the Senior Notes and Term Loan Credit Facilities as the company’s principal funded-debt instruments. It states that the company complies with all covenants related to the Senior Notes. The note also explains that term loans carry floating interest rates linked to the SOFR index, creating exposure to changes in short-term rates. It further indicates that incremental issuance under the related programs matures within a short period after issuance.

- Analyst inference: The weaker half-year revenue and net-income results, alongside stronger quarterly results, suggest that the later reporting window was more favorable than the earlier portion of the year. The data do not establish whether that improvement will continue, so the next period should be assessed for persistence rather than treated as a confirmed trend. The parallel revenue and net-income movements indicate that the company’s earnings direction remains sensitive to top-line conditions, but the filing does not quantify the relationship.

- Counter-evidence: The debt disclosures do not describe a covenant breach, event of default, or acceleration of the Senior Notes. The company’s statement that it is in compliance with all related covenants provides reassurance that the reported debt structure is not currently presented as a covenant problem. The cited passage also distinguishes estimated fair value from carrying value for long-term debt, indicating that market valuation differences should not be confused with an immediate repayment requirement.

- Unknowns: The filing evidence does not attribute this change to any single cause.. The filing does not disclose segment-level detail for the revenue dimension, so The filing evidence does not disclose segment-level detail for this dimension.. The filing evidence also contains no peer or industry comparison, so The filing evidence contains no peer or industry comparison..

- Metrics to watch next period: the extension or reversal of the quarterly revenue increase; whether the half-year net-income decline narrows; the effect of SOFR-linked rates on floating-rate term-loan interest expense; any change in Senior Notes covenant compliance or default disclosures; the timing of additional borrowing and repayment; and movements in long-term debt fair value relative to carrying value. Investors may also compare the pattern with other interim filings, such as CMS Energy Reports Softer Bottom Line Against Higher Contract Revenue, while recognizing that the companies operate in different industries.